Pharma/Biotech Update: Factor Xa Drug Reaches Phase II
January 7, 2014; Posted by: WeBleed staff
New oral drug featured in recent study in Russia.
If you currently suffer from a cardiovascular disorder like deep vein thrombosis or thromboembolism, a new drug in the pipeline may be here soon to help you out.
A new oral drug called TeaRxaban is currently in Phase II development for one precise goal: prevent complications in those who suffer from bleeding disorders.
Dr. Kirill Volynchik Director of Development at TeaRx LLC states that “preclinical and clinical studies of TeaRxaban demonstrated that the drug has a high therapeutic index and its pharmacological properties and safety may have several advantages over currently approved anticoagulants. Launch of such innovative Russian drug with potentially higher efficacy and safety than drugs in current clinical practice is of strategic significance for better treatment of patients in Russia.”
Sounds like the new pharmaceutical drug is passing through it’s studies with flying colors according to Marketwired. More information will be released as TeaRxaban passes through it’s clinical studies.
Photo Credit: TeaRx
webleed.org – your source for bleeding news!
